Skip to Main Content

Business Concentrates

March 8, 2010
Volume 88, Number 10
p. 19

AstraZeneca Details Deep R&D Cuts

Lisa M. Jarvis

  • Print this article
  • Email the editor

Text Size A A

Following a January announcement of plans for deep R&D cuts, AstraZeneca has revealed which facilities and therapeutic areas will be affected. The company is ending discovery research in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression and anxiety, hepatitis C, and vaccines other than respiratory syncytial virus and influenza. In the U.K., Astra­Zeneca plans to close its Leices­ter­shire and Cambridge sites, affecting roughly 1,000 researchers, and end pharmaceutical development work at the Avlon facility near Bristol. AstraZeneca will close its Lund, Sweden, site. It will also end discovery research in Wilmington, Del., affecting some 550 scientists.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!